Subsequent Applications

BI’s technology will address (a) other autoimmune diseases such as Diabetes Mellitus type-1 (b) transplant patients (solid organs) thus minimizing cytotoxic  drugs dozes. 

This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, visit About Cookies page.